ReviewWorld journal of biological chemistry2014
In 2014, can we do better than CA125 in the early detection of ovarian cancer?
Review in World journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Research on the inhibitory effect of hydrogen gas on ovarian cancer and potential mechanisms.European journal of medical research · 2025Article
- Exosome-transmitted miR-30a-5p enhances cell proliferation, migration, and invasion in ovarian cancer.Cell division · 2023Article
- Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent.Pharmaceutics · 2022Article
- Review
- Effect of Serum Level of Human Epididymis Protein 4 and Interleukin-6 as Biomarkers in Patients with Adnexal Mass.Archives of Razi Institute · 2022Article
- Diagnostic performance of microRNA-34a, let-7f and microRNA-31 in epithelial ovarian cancer prediction.Journal of gynecologic oncology · 2022Article
- Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature.Journal of personalized medicine · 2021Review
- Article
- Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers.Cancer prevention research (Philadelphia, Pa.) · 2020Review
- Ovarian Cancer Biomarkers: Moving Forward in Early Detection.Advances in experimental medicine and biology · 2020Review
- SPOCD1 accelerates ovarian cancer progression and inhibits cell apoptosis via the PI3K/AKT pathway.OncoTargets and therapy · 2020Article
- An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.International journal of molecular sciences · 2019Article
- A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds.Journal of cancer metastasis and treatment · 2019Article
- Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.International journal of cancer · 2018Article
- Overexpression of Pyruvate Kinase Type M2 (PKM2) Promotes Ovarian Cancer Cell Growth and Survival Via Regulation of Cell Cycle Progression Related with Upregulated CCND1 and Downregulated CDKN1A Expression.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.Journal of translational medicine · 2018Article
- Lycopene Protects Against Spontaneous Ovarian Cancer Formation in Laying Hens.Journal of cancer prevention · 2018Article
- Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?Disease markers · 2018Article
- Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting IκBα.OncoTargets and therapy · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a lethal gynecologic malignancy with greater than 70% of women presenting with advanced stage disease. Despite new treatments, long term outcomes have not significantly changed in the past 30 years with the five-year overall survival remaining between 20% and 40% for stage III and IV disease. In contrast patients with stage I disease have a greater than 90% five-year overall survival. Detection of ovarian cancer at an early stage would likely have significant impact on mortality rate. Screening biomarkers discovered at the bench have not translated to success in clinical trials. Existing screening modalities have not demonstrated survival benefit in completed prospective trials. Advances in high throughput screening are making it possible to evaluate the development of ovarian cancer in ways never before imagined. Data in the form of human "-omes" including the proteome, genome, metabolome, and transcriptome are now available in various packaged forms. With the correct pooling of resources including prospective collection of patient specimens, integration of high throughput screening, and use of molecular heterogeneity in biomarker discovery, we are poised to make progress in ovarian cancer screening. This review will summarize current biomarkers, imaging, and multimodality screening strategies in the context of emerging technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.